<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Signaling by EGFR in Cancer" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">The pathway "Signaling by EGFR in Cancer" shows signaling by constitutively active EGFR cancer variants in the context of "Signaling by EGFR", allowing users to compare cancer events with the wild-type EGFR events. Red lines emphasize cancer related events and physical entities, while wild-type entities and events are shaded. Please refer to "Signaling by Ligand-Responsive EGFR Variants in Cancer", "Signaling by EGFRvIII in Cancer" and "Signaling by Overexpressed Wild-Type EGFR in Cancer" for detailed pathway summations.
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=1643713 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 1643713</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Orlic-Milacic, Marija</Comment>
  <Attribute Key="reactome_id" Value="1643713" />
  <Graphics BoardWidth="609.0" BoardHeight="339.0" />
  <DataNode TextLabel="Signaling by&#xA;Ligand-Responsive&#xA;EGFR Variants in&#xA;Cancer" GraphId="ee792" Type="Pathway">
    <Comment Source="Reactome">Ligand-responsive EGFR cancer variants harbor mutations in the kinase domain or point mutations in the extracellular domain. These altered EGFR proteins are able to signal in the absence of ligands, but their ligand binding ability is preserved and downstream signaling is potentiated when ligand is available (Greulich et al. 2005, Lee et al. 2006).</Comment>
    <BiopaxRef>a4c</BiopaxRef>
    <BiopaxRef>ad3</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="370.0" CenterY="192.5" Width="412.0" Height="63.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5637815" />
  </DataNode>
  <DataNode TextLabel="Signaling by&#xA;Overexpressed&#xA;Wild-Type EGFR in&#xA;Cancer" GraphId="c3e97" Type="Pathway">
    <Comment Source="Reactome">Signaling by EGFR is frequently activated in cancer through genomic amplification of the EGFR locus, resulting in over-expression of the wild-type protein (Wong et al. 1987).</Comment>
    <BiopaxRef>e77</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="371.0" CenterY="277.0" Width="414.0" Height="64.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5638302" />
  </DataNode>
  <DataNode TextLabel="Signaling by&#xA;EGFRvIII in Cancer" GraphId="ef048" Type="Pathway">
    <Comment Source="Reactome">EGFRvIII (EGFR V30_R297delinsG) is the most prevalent EGFR variant in glioblastoma, but it is also found in other cancer types. In-frame deletion of the ligand binding domain in EGFRvIII is frequently accompanied with genomic amplification, resulting in over-expression of EGFRvIII. EGFRvIII dimerizes and autophosphorylates spontaneously and is therefore constitutively active (Fernandes et al. 2001)</Comment>
    <BiopaxRef>e57</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="372.0" CenterY="113.0" Width="414.0" Height="60.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-5637812" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a4c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">16187797</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Greulich H, Chen TH, Feng W, JÃ¤nne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ad3">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17177598</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e77">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">3477813</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e57">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11087732</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Fernandes H, Cohen S, Bishayee S.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

